Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 8,333 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Clear all
Completed Phase 2 Interventional Results available

Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study

NCT01077401
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 29, 2026, 4:32 AM EDT
Recruiting Not applicable Interventional

Diabetic Foot Ulcer Imaging- Study 2

NCT03942081
View directory record Official record
Conditions
Foot Ulcer, Foot Ulcer, Diabetic
Interventions
Ulcer Measurement Software
Device
Lead sponsor
Linnea Polgreen
Other
Eligibility
21 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 29, 2026, 4:32 AM EDT
Completed No phase listed Observational

Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection

NCT05897528
View directory record Official record
Conditions
COVID-19, Diabetes Mellitus, COVID-19 Pneumonia, COVID-19 Respiratory Infection
Interventions
No Intervention
Other
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
589 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 29, 2026, 4:32 AM EDT
Completed No phase listed Observational

Analysis of Glycemic Control in Type 1 Diabetes Patients Using Hybrid Closed Loop Insulin Pump Therapy (Medtronic 670G)

NCT04051632
View directory record Official record
Conditions
Biomedical Technology, Type 1 Diabetes
Interventions
Medtronic 670G insulin pump
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 25 Years
Enrollment
96 participants
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 9, 2019 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes

NCT00849563
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Standardized Risk Assessment
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 29, 2026, 4:32 AM EDT
Active, not recruiting Phase 3 Interventional

Trial to Assess Chelation Therapy in Critical Limb Ischemia

NCT03982693
View directory record Official record
Conditions
Critical Limb Ischemia, Diabetes
Interventions
Edetate Disodium, Placebo
Drug · Other
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community-Based Nutrition-Lifestyle Therapy for Pregnant Latina Women With Diabetes

NCT06218147
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mel Gestational - in Pregnancy
Interventions
Nutrition-behavior lifestyle program
Behavioral
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 29, 2026, 4:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Adherence to Digital Health Technologies Among Hispanic/Latino Adults With or At Risk of Type 2 Diabetes:

NCT04820348
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Depression, Anxiety, Diet Habit
Interventions
Not listed
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Not applicable Interventional Results available

Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes

NCT01529385
View directory record Official record
Conditions
Edema
Interventions
mild compression diabetic sock, Standard diabetic sock
Device
Lead sponsor
Rosalind Franklin University of Medicine and Science
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 29, 2026, 4:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study

NCT07298408
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies
Interventions
Cannabidiol (CBD) oral solution, Full-Spectrum CBD hemp extract oral solution, Placebo in MCT oil oral solution
Drug
Lead sponsor
Florida A&M University
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Peer Coaching for Low-Income Patients With Diabetes in Primary Care

NCT01040806
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Usual care, Health coaching
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 29, 2026, 4:32 AM EDT
Recruiting No phase listed Observational

Registry for Stage 2 Type 1 Diabetes

NCT06481904
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
TZIELD (teplizumab-mzwv)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
37
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects

NCT02886884
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
20 million Allogeneic Mesenchymal Human Stem Cells, 100 million Allogeneic Mesenchymal Human Stem Cells
Drug
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 29, 2026, 4:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Impact of Fitness on Vascular Dysfunction in Adolescents With Type 1 Diabetes

NCT01337947
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Definity microbubbles
Drug
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Patient-centered Goal Setting in the National Diabetes Prevention Program

NCT05559515
View directory record Official record
Conditions
PreDiabetes
Interventions
NDPP-Flex, NDPP
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 29, 2026, 4:32 AM EDT
Recruiting Phase 3 Interventional

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Risk
Interventions
Zenagamtide, Insulin glargine U-100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
109
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

Type 1 Diabetes Data Acquisition and Transfer Adherence Study

NCT03228004
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glooko MeterSync
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Diabetes Go Mobile! Pilot Study

NCT02858648
View directory record Official record
Conditions
Diabetes
Interventions
Behavior intervention with smart phone based self-monitoring, Behavior intervention with paper diary based self-monitoring
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 74 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Phase 3 Interventional

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

NCT00039026
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
126
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Naltrexone and Hypoglycemia in Type 1 Diabetes

NCT01053078
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Unawareness
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Real-time Reminders To Decrease Late or Missed Meal Boluses

NCT03970889
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Klue
Device
Lead sponsor
Stanford University
Other
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

NCT01472185
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
57
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Improving Medication Safety and CVD Risk Factor Control in Kidney Transplant Recipients

NCT02763943
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes Mellitus, Medication Adherence
Interventions
Pharmacist-led, technology enabled education intervention
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 29, 2026, 4:32 AM EDT
Completed Phase 3 Interventional

Treatment of Peripheral Neuropathy in Patients With Diabetes

NCT00044421
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
30
States / cities
Mesa, Arizona • Irvine, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 29, 2026, 4:32 AM EDT